Anupam Rasayan and Mates Visa acquire control of Bliss GVS Pharma with 47.95% stake
As filed · Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026 relating to the consummation of the transaction contemplated in the share purchase agre
M&AMixedMajormateriality 82 out of 100
What happened
FactMates Visa Consultancy completed the acquisition of 5,09,84,595 Bliss GVS Pharma shares, representing 47.95% of its equity capital. Together with Anupam Rasayan India, it now controls the company and has become a promoter; three nominee directors were appointed and Managing Director Narsimha Shibroor Kamath resigned, effective September 28, 2026.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Watch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
Evidence
How CapitSignal classified this
- Reasoning:
- The transaction results in a substantial change in ownership, promoter control and board composition. The simultaneous managing director resignation creates an executive leadership transition, while the filing provides no transaction valuation or financial impact.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%